Libroxar

Buprenorphine/Naloxone, the active ingredient in Libroxar, is a Partial opioid agonist / opioid antagonist combination presented as a sublingual formulation for sublingual use. It treats opioid dependence and opioid use disorder in adults.

GNH USA supplies Libroxar as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Libroxar is used in the management of opioid dependence and related disorders, acting on the opioid receptor system to reduce withdrawal and cravings.

- Opioid dependence: helps maintain abstinence by reducing withdrawal symptoms and cravings. - Opioid use disorder: supports long‑term recovery and stabilisation in patients with opioid misuse. - Relapse prevention: lowers the risk of relapse by providing a controlled opioid effect while blocking full agonist activity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Constipation: reduced bowel movements. - Headache: transient cranial pain. - Sweating: increased perspiration, especially at night. - Insomnia: difficulty falling or staying asleep. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing, potentially life‑threatening. - Severe hypotension: marked drop in blood pressure. - Hepatic injury: abnormal liver function tests. - QT interval prolongation: cardiac rhythm disturbance. - Anaphylaxis: severe allergic reaction with rash, swelling, or airway compromise. - Overdose: signs include extreme sedation, pinpoint pupils, and respiratory failure.

Libroxar should be prescribed after a thorough clinical assessment and patients should be monitored for safety. - Assess patient history: review prior opioid use, liver function, and psychiatric conditions. - Monitor respiratory status: watch for signs of depression, especially during initiation. - Avoid use in acute severe asthma: risk of bronchospasm. - Use caution with CNS depressants: combine only under close supervision. - Educate on sublingual administration: ensure tablet is placed under the tongue until fully dissolved. - Store at ambient temperature: keep in the original pack, protect from moisture.

Libroxar can interact with several drug classes; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid): - Opioid analgesics: additive respiratory depression risk. - Benzodiazepines: heightened sedation and respiratory compromise. - Alcohol: increased central nervous system depression. - MAO inhibitors: potential for severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise buprenorphine levels. - CYP3A4 inducers (e.g., rifampicin): may reduce efficacy. - Other CNS depressants (e.g., antihistamines): monitor for enhanced sedation.